Valuation : Defence Therapeutics Inc.

Market Cap 33.35M 24.09M 20.79M 19.58M 17.84M 2.28B 33.6M 232M 89.97M 1.16B 90.48M 88.5M 3.82B P/E 2024
-2.5x
P/E 2025 -9.9x
Enterprise Value 33.62M 24.29M 20.96M 19.74M 17.99M 2.29B 33.87M 234M 90.7M 1.17B 91.21M 89.22M 3.85B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
66.13%
Yield 2024 *
-
Yield 2025 -
1 week-3.70%
Current month-3.70%
1 month+22.35%
3 months-13.33%
6 months-14.75%
Current year-27.78%
1 week 0.48
Extreme 0.48
0.56
1 month 0.37
Extreme 0.37
0.59
Current year 0.36
Extreme 0.365
0.74
1 year 0.36
Extreme 0.365
0.93
3 years 0.36
Extreme 0.365
3.04
5 years 0.36
Extreme 0.365
8.15
10 years 0.36
Extreme 0.365
8.15
Manager TitleAgeSince
Chief Executive Officer - 01/08/2026
Director of Finance/CFO 55 20/12/2024
Chief Operating Officer - 17/08/2026
Director TitleAgeSince
Chairman 53 01/08/2026
Director/Board Member 64 05/01/2021
Director/Board Member - 27/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
8/1/26 A Option

Chief Executive Officer

200,000 0.2639%
8/1/26 A Option

Founder

200,000 0.2639%
6/3/26 A Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.70%-34.18%-82.67% 28.35M
+0.97%-0.75%+3.51%+17.79% 49.74B
-0.40%-3.13%+427.93%+519.44% 44.98B
+2.82%+1.73%+44.79%+20.44% 42.52B
+0.88%-3.67%+9.02%+76.72% 40.78B
-0.90%-1.74%+15.20%+48.44% 32.89B
+2.15%+6.13% - - 17.09B
+1.34%-4.40%+25.03%+123.24% 16.28B
+1.70%-0.05%+18.53%+28.09% 14.4B
+2.81%-1.64%+80.01%+42.08% 13.48B
Average +1.14%-1.99%+65.54%+88.18% 27.22B
Weighted average by Cap. +1.03%-2.25%+93.88%+128.65%

Financials

2024 2025
Net sales - -
Net income -13.19M -9.53M -8.22M -7.75M -7.06M -900M -13.29M -91.72M -35.59M -460M -35.8M -35.01M -1.51B -3.52M -2.54M -2.2M -2.07M -1.88M -240M -3.55M -24.48M -9.5M -123M -9.56M -9.35M -404M
Net Debt 1.69M 1.22M 1.05M 992K 904K 115M 1.7M 11.75M 4.56M 58.97M 4.59M 4.48M 194M 272K 196K 169K 160K 145K 18.55M 274K 1.89M 733K 9.49M 738K 721K 31.16M
Logo Defence Therapeutics Inc.
Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.
Employees
-
Date Price Change Volume
02/09/26 CA$0.5200 0.00% 32,595
01/09/26 CA$0.5200 -3.70% 13,443
31/08/26 CA$0.5400 +3.85% 75,296
28/08/26 CA$0.5200 +1.96% 24,620
27/08/26 CA$0.5100 -5.56% 19,000